Akebia Therapeutics Approves Stock Plan Amendment at Meeting

Akebia Therapeutics ( (AKBA) ) has shared an announcement.

At its Annual Meeting on June 10, 2025, Akebia Therapeutics‘ stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available by 18,900,000. Additionally, the election of two Class II directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the accounting firm were also confirmed. This amendment and the meeting’s outcomes are expected to enhance Akebia’s ability to attract and retain talent, aligning employee incentives with shareholder interests, which could strengthen its market position.

The most recent analyst rating on (AKBA) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Akebia Therapeutics stock, see the AKBA Stock Forecast page.

Spark’s Take on AKBA Stock

According to Spark, TipRanks’ AI Analyst, AKBA is a Neutral.

Akebia Therapeutics faces significant financial challenges, including declining revenue and high leverage. However, the strong launch of Vafseo and strategic market expansion provide some optimism. Despite these positive developments, the stock remains a risk due to ongoing financial instability and valuation challenges.

To see Spark’s full report on AKBA stock, click here.

More about Akebia Therapeutics

Akebia Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing therapeutics for patients with kidney disease. The company is known for its efforts to provide innovative treatments to improve the lives of those affected by kidney-related conditions.

Average Trading Volume: 5,578,628

Technical Sentiment Signal: Buy

Current Market Cap: $937.6M

See more data about AKBA stock on TipRanks’ Stock Analysis page.